* AP…
The U.S. is recommending a “pause” in using the single-dose Johnson & Johnson COVID-19 vaccine to investigate reports of potentially dangerous blood clots.
The Centers for Disease Control and Prevention and the Food and Drug Administration said Tuesday they were investigating unusual clots that occurred 6 to 13 days after vaccination. The clots occurred in veins that drain blood from the brain and occurred together with low platelets. All six cases were in women between the ages of 18 and 48; there was one death and all remained under investigation.
* IDPH…
In accordance with recommendations from the U.S. Centers for Disease Control and Prevention (CDC) and the U.S. Food and Drug Administration (FDA), the Illinois Department of Public Health (IDPH) will pause the use of the Johnson & Johnson (J&J) COVID-19 vaccine out of an abundance of caution. The CDC and FDA are reviewing data involving six reported U.S. cases of a rare and severe type blood clot in individuals after receiving the J&J vaccine.
IDPH has notified all Illinois COVID-19 providers throughout the state to discontinue use of the J&J vaccine at this time. In order to keep appointments, IDPH is strongly advising providers to use Pfizer-BioNTech and Moderna vaccines.
Moderna and Pfizer make up the vast majority of doses on hand in the State of Illinois. This week, the state’s allocation of J&J was 17,000 doses. For the week of April 18, 2021, the expected allocation for the State is 483,720 total doses. Of that total allocation, 5,800 doses were expected to be J&J.
Per the federal health authorities, people who have received the J&J vaccine who develop severe headache, abdominal pain, leg pain, or shortness of breath within three weeks after vaccination should contact their health care provider. Patients with other clinical questions should contact their health care provider.
IDPH will continue to update the public as additional information becomes available.
*** UPDATE 1 *** Johnson & Johnson…
The safety and well-being of the people who use our products is our number one priority. We are aware of an extremely rare disorder involving people with blood clots in combination with low platelets in a small number of individuals who have received our COVID-19 vaccine. The United States Centers for Disease Control (CDC) and Food and Drug Administration (FDA) are reviewing data involving six reported U.S. cases out of more than 6.8 million doses administered. Out of an abundance of caution, the CDC and FDA have recommended a pause in the use of our vaccine.
In addition, we have been reviewing these cases with European health authorities. We have made the decision to proactively delay the rollout of our vaccine in Europe.
We have been working closely with medical experts and health authorities, and we strongly support the open communication of this information to healthcare professionals and the public.
The CDC and FDA have made information available about proper recognition and management due to the unique treatment required with this type of blood clot. The health authorities advise that people who have received our COVID-19 vaccine and develop severe headache, abdominal pain, leg pain, or shortness of breath within three weeks after vaccination should contact their health care provider.
For more information on the Janssen COVID-19 vaccine, click here.
A commenter asked how many people would die from contracting COVID-19 as a result of this pause. It’s a good question.
…Adding… Another good point…
*** UPDATE 2 *** Block Club Chicago…
The state will send 50,000 doses of the Moderna and Pfizer vaccines to Chicago as the city suspends using its Johnson & Johnson doses. […]
The pause is only expected to last several days, officials have said.
The one-shot vaccine has been administered to tens of thousands of people in Chicago, and officials hoped that, as supply of the doses increased, it would play a significant role in getting residents vaccinated as quickly as possible — especially with cases on the rise in the city.
*** UPDATE 3 *** IDPH…
The Illinois Department of Public Health (IDPH) is developing and implementing plans to move forward with COVID-19 vaccinations in Illinois after putting a pause on administration of the Johnson & Johnson (Janssen) vaccine, including robust communication with all providers and the transfer of 50,000 doses of COVID-19 vaccine to Chicago.
Earlier today, at the recommendation of the U.S. Centers for Disease Control and Prevention (CDC) and the U.S. Food and Drug Administration (FDA), IDPH paused the use of the J&J COVID-19 vaccine out of an abundance of caution. The CDC and FDA are reviewing data involving six reported U.S. cases of a rare and severe type blood clot in individuals after receiving the J&J vaccine, out of a total of more than six million Americans who have received the J&J vaccine. In Illinois, of the total 7.3 million doses administered to date, 4% or approximately 290,000 have been J&J. These individuals remain fully vaccinated and do not need to seek out an alternate vaccine. People vaccinated with J&J should consult with their medial provider if they develop severe headache, abdominal pain, leg pain, or shortness of breath within three weeks after vaccination.
“Public health officials made a commitment that any safety signals that came up concerning COVID-19 vaccines would be fully addressed in a transparent manner, which is what is occurring right now with the J&J vaccine,” said IDPH Director Dr. Ngozi Ezike. “The blood clot cases appear to be extremely rare and there are no reported cases associated with either the Pfizer-BioNTech or the Moderna vaccines. IDPH is taking immediate action to ensure as little disruption to Illinois residents as possible during this pause, and I strongly encourage people to continue to get vaccinated. Millions upon millions of people have already been safely vaccinated and it will take millions more before we can put this pandemic behind us.”
Upon learning of the recommendation, IDPH took the following actions to ensure COVID-19 vaccine providers and health care workers in Illinois were aware of the pause and received the support they needed to adjust their planning:
• Immediately sent notification about the pause to COVID-19 providers, local health departments, and health care providers via the State of Illinois Rapid Electronic Notification system, which included follow-up calls, text, and emails.
• Directly emailed and called all local health departments through IDPH Emergency Response Coordinators, to assess impact and work to mitigate using Pfizer-BioNTech and Moderna vaccines.
• Connected with all mass vaccination sites, Illinois National Guard vaccination missions, and one-day J&J clinics scheduled in EMTrack to develop alternate plans where necessary and ensure the least amount of disruption possible on individuals with appointments.
• Sent notification to hospitals, emergency departments, physicians, and other health care providers about treatment for this specific type of blood clot
The pause on the J&J vaccine will not have a large impact on state vaccination efforts as the Moderna and Pfizer-BioNTech vaccines make up the vast majority of doses on hand in the State of Illinois. No state-supported mass vaccination sites will be closed and no rapid response team clinics, faith-based or equity clinics, or rural clinics have been cancelled at this time. They will all move forward with a different type of vaccine.
The total allocation of J&J vaccine to Illinois, including Chicago, is 760,300, of which 290,615 doses have been administered. This week, the state’s allocation of J&J was 17,000 doses. For the week of April 18, 2021, the expected allocation for the State is 483,720 total doses. Of that total allocation, 5,800 doses were expected to be J&J.
In an effort to vaccinate as many people as possible across Illinois, the State is allocating 50,000 first doses of Moderna and Pfizer-BioNTech vaccine to the City of Chicago over the next seven days to help meet demand. The State will also be allocating 50,000 doses to Chicago when second doses come due to be administered.
IDPH encourages people to register with V-safe After Vaccination Health Checker, a smartphone-based tool that uses text messages and web surveys to provide personalized health check-ins after you receive a COVID-19 vaccine. For more information on v-safe, go to https://www.cdc.gov/coronavirus/2019-ncov/vaccines/safety/vsafe.html.
